Hospital
ST. Joseph's Hospital, INC.
ST. Joseph's Hospital, INC. was paid $4.70M by Medicaid between Jan 2018 and Nov 2024, across 78 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoST. JOSEPH'S HOSPITAL, INC.
TAMPA, FL 33607
TAMPA, FL 33607
33aNPI1346519816assigned 12/29/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.70M
24GClaims78,858
24DCodes billed78
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#83 of 163
Median peer was paid$4.77M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GORKEN, LYNDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,913 | $61K | |
| 2019 | 27,290 | $1.60M | |
| 2020 | 18,249 | $976K | |
| 2021 | 15,264 | $836K | |
| 2022 | 11,829 | $671K | |
| 2023 | 3,565 | $421K | |
| 2024incomplete | 748 | $141K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 8,937 | 7,524 | $1.08M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 2,606 | 2,288 | $634K |
| 59899 | 9.7% | 7,679 | 5,821 | $458K | |
| 81003 | 8.5% | 5,836 | 4,906 | $400K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 6.0% | 4,843 | 4,450 | $282K |
| 80053 | Comprehensive metabolic panel | 6.0% | 2,334 | 1,890 | $281K |
| 59025 | Fetal non-stress test | 5.4% | 2,227 | 1,077 | $253K |
| 84112 | 3.5% | 565 | 506 | $163K | |
| 76819 | Fetal biophysical profile; without non-stress testing | 3.4% | 1,515 | 891 | $159K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 2.6% | 2,196 | 2,073 | $123K |
| 36415 | Collection of venous blood by venipuncture | 2.4% | 3,721 | 2,851 | $112K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.3% | 864 | 762 | $107K |
66 more codes
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.6% | 1,295 | $77K |
| 87480 | 1.6% | 1,461 | $75K | |
| 84702 | 1.5% | 1,737 | $69K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 1,606 | $58K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 1.1% | 2,512 | $50K |
| 76825 | <1% | 166 | $39K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,379 | $37K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 405 | $32K |
| 99285 | Emergency room visit (most serious) | <1% | 304 | $28K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 694 | $25K |
| 82731 | <1% | 79 | $24K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,248 | $23K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 222 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 384 | $15K |
| 86850 | <1% | 1,367 | $12K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 580 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 523 | $9K |
| 86900 | <1% | 1,594 | $8K | |
| 76801 | <1% | 1,681 | $8K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 65 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,744 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 28 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 1,146 | $4K |
| 84156 | <1% | 476 | $4K | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 47 | $3K |
| 93325 | <1% | 143 | $3K | |
| 82948 | <1% | 89 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 58 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 42 | $852.43 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 33 | $842.24 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,536 | $783.70 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 192 | $767.90 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 211 | $765.44 |
| 86901 | <1% | 1,594 | $753.76 | |
| 76642 | <1% | 17 | $633.05 | |
| 87660 | <1% | 1,465 | $579.85 | |
| 77080 | <1% | 35 | $532.80 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 157 | $472.03 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 67 | $347.95 |
| 76827 | <1% | 129 | $330.47 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 373 | $306.58 |
| 87510 | <1% | 1,461 | $274.24 | |
| 76820 | <1% | 110 | $225.80 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 384 | $75.32 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 790 | $46.58 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 50 | $30.15 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 215 | $6.33 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 598 | $5.97 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 118 | $2.40 |
| 82570 | <1% | 400 | $1.74 | |
| 84550 | <1% | 128 | $0.87 | |
| 85027 | <1% | 19 | $0.62 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 39 | $0.60 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 29 | $0.31 |
| 87077 | <1% | 16 | $0.31 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 65 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 15 | $0.00 |
| 0352U | 0% | 67 | $0.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 44 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 21 | $0.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 15 | $0.00 |
| 86780 | 0% | 12 | $0.00 | |
| 0353U | 0% | 14 | $0.00 | |
| 0100U | 0% | 14 | $0.00 | |
| 77065 | Tomosynthesis, mammo | 0% | 13 | $0.00 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGORKEN, LYNDA (VP, PATIENT FINANCIAL SERVICES)
Parent organizationST. JOSEPH'S HOSPITAL, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.